SCHEMBL4361764

SCHEMBL4361764

c1ccc(-c2cncc(-c3cc4ccccc4nc3-c3ccccc3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.51
▸ PSMB5 P28074 1/20 0.50
▸ AKT1 P31749 1/20 0.50
▸ CYP2A6 P11509 1/20 0.44
▸ PDGFRB P09619 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ CYP11B1 P15538 1/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ PIK3CD O00329 1/20 0.40
▸ PIK3CA P42336 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361761 0.94 PSMB5 (0.50) PDE10APSMB5AKT1CYP2A6PDGFRB
SCHEMBL29374375 0.84 PSMB5 (0.65) PDE10APSMB5AKT1NPC1RAB9A
SCHEMBL3359420 0.84 PSMB5 (0.65) PDE10APSMB5AKT1NPC1RAB9A
SCHEMBL27656250 0.84 CYP11B1 (0.57) PDE10APSMB5AKT1CYP2A6NPC1
SCHEMBL31054483 0.83 PSMB5 (0.63) PDE10APSMB5AKT1NPC1RAB9A
Ammonia Solution, Strong SCHEMBL28129677 0.83 PSMB5 (0.63) PDE10APSMB5AKT1NPC1RAB9A
SCHEMBL28284780 0.81 CYP2A6 (0.56) PDE10APSMB5AKT1CYP2A6NPC1
SCHEMBL28846224 0.80 PSMB5 (0.56) PDE10APSMB5AKT1PDGFRBPDGFRA
SCHEMBL22673549 0.79 CYP11B2 (0.61) PSMB5AKT1CYP2A6NPC1RAB9A
SCHEMBL26551805 0.77 PSMB5 (0.61) PDE10APSMB5AKT1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482456-B2 antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol MERCK FROSST CANADA 2009-01-27 — — US disclosed
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors MERCK FROSST CANADA & CO. (CA) 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors PDE4A, PDE4B, PDE3B PDE10A 14/4885PSMB5 2238/4885AKT1 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback